Royce & Associates LP Uni Qure N.V. Transaction History

Royce & Associates LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 06, 2021	SELL	$29.97 - $37.17 $1.62 Million - $2.01 Million	-54,000 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$40.01 - $73.97 $240,060 - $443,820	-6,000 Reduced 10.0%	54,000 $2.56 Million
Q3 2018 Nov 13, 2018	SELL	$29.75 - $43.08 $1.19 Million - $1.72 Million	-40,000 Reduced 40.0%	60,000 $2.18 Million
Q2 2018 Aug 09, 2018	SELL	$21.96 - $39.94 $549,000 - $998,500	-25,000 Reduced 20.0%	100,000 $3.78 Million
Q4 2017 Feb 09, 2018	BUY	$9.47 - $19.59 $1.18 Million - $2.45 Million	125,000	125,000 $2.45 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.